Navigation Links
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Date:1/4/2012

SAN FRANCISCO, Jan. 4, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming 30th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel on Wednesday, January 11, 2012 at 8:30 a.m. Pacific time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until February 12, 2012.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled seven approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-181, a novel mu-opioid analgesic, has completed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
2. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Therapeutics to Webcast R&D Day on November 12th
5. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
6. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
7. Nektar Announces Retirement of Irwin Lerner from Board of Directors
8. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
9. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... could improve the health of your heart, researchers have ... used a standard TENS machine like those designed to ... tragus, the small raised flap at the front of ... , The stimulation changed the influence of the nervous ... that can drive failing hearts too hard. , Professor ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... 2014 Research and Markets  has announced the ... Global Strategic Business Report" report to their offering. ... Oxide Fuel Cells (SOFCs) in US$ Thousands. The report provides ... , Europe , Asia-Pacific ... provided for the period 2012 through 2020. Market data and ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
Breaking Biology Technology:'Tickling' your ear could be good for your heart 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3
... Aug. 24, 2011 United Therapeutics Corporation (NASDAQ: ... of its FREEDOM-C(2) Phase 3 trial of treprostinil ... formulation of treprostinil, a stable synthetic form of ...  Preliminary analysis demonstrates that the trial did not ...
... Lake, N.Y. New research from the Trudeau Institute ... (LAIV), commonly known as FluMist, elicits protection. The ... Vaccine . The journal article is entitled "Live attenuated ... and was authored by Trudeau Institute scientist Dr. Laura ...
... Mich.---A delicate balance of atomic forces can be exploited ... attribute that,s important for many nanotech applications but hard ... The same type of forces are at work bringing ... supercluster structures in this research are in many ways ...
Cached Biology Technology:FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 2FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 3FREEDOM-C(2) Trial of Oral Treprostinil in Pulmonary Arterial Hypertension Does Not Meet Primary Endpoint 4Trudeau Institute announces a discovery in how FluMist elicits protection 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2
(Date:8/19/2014)... release is available in German . ... inherently intermittent energy sources. If a large amount of electricity ... future, excess energy will have to be stored during productive ... existing storage capacities are far from adequate for the purpose. ... One important focus lies on battery systems that used to ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s not ... the Philippine tarsier: a tiny, adorable and downright "cool" primate ... that Americans are familiar with," said Rafe Brown, curator-in-charge at ... eyes and ears; an extremely cute, furry body; a long ... expanded fingers and toe tips that look a bit like ...
(Date:8/19/2014)... purchased at retail seafood counters in 10 different ... expose consumers to unexpectedly high levels of mercury, ... present a fish of the same species, but ... mislabeling offense, according to new research by University ... of seafood is essential to allow consumers to ...
Breaking Biology News(10 mins):Asian inventions dominate energy storage systems 2Asian inventions dominate energy storage systems 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Seafood substitutions can expose consumers to unexpectedly high mercury 2Seafood substitutions can expose consumers to unexpectedly high mercury 3
... FL (May 21, 2010).The University of Miami (UM) has ... the Howard Hughes Medical Institute (HHMI) to strengthen the ... and Sciences, where the program resides, will use the ... from groups traditionally underrepresented in the sciences to pursue ...
... at the University of Oxford and Royal Holloway University of London ... Bt works best if applied to young plants and ... is published today (20 May) in the open-access journal PLoS ... Bacillus thuringiensis is a common method for controlling a ...
... -- At a recent Specialty Coffee Association of America ... to increase the overall quality and availability of specialty ... new effort, called the Global Coffee Quality Research Initiative ... coffee roasters and agricultural researchers in partnership with the ...
Cached Biology News:UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2New global coffee research initiative announced 2New global coffee research initiative announced 3
... DNA Engine Opticon 2 real-time PCR detection ... for fluorescence excitation (470-505 nm) and two ... 540-700 nm). The Opticon 2 system is ... which includes a thermal gradient feature. This ...
Fingerprinting II Informatix cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to ...
... II Informatix dimensioning ... optional module that ... analysis, multidimensional scaling, ... MANOVA, and self-organizing ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Biology Products: